Literature DB >> 2499462

Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome.

M Huber1, S Kästner, J Schölmerich, W Gerok, D Keppler.   

Abstract

The cysteinyl leukotrienes, comprising leukotriene C4 and its metabolites, are biologically most active mediators, eliminated from the blood circulation by the liver and the kidneys. The urine of normal subjects and of patients with hepatic and/or renal failure was analysed for endogenous cysteinyl leukotrienes. The leukotriene metabolites were separated by reversed-phase high-performance liquid chromatography and subsequently quantified by radioimmunoassay. Leukotriene E4 was detected in all urine samples analysed. Its mean concentration increased from 0.3 nmol l-1 in healthy subjects to 0.8 nmol l-1 in patients with liver cirrhosis. In patients with hepatorenal syndrome leukotriene E4 averaged 7.8 nmol l-1; in addition, N-acetyl-leukotriene E4 was detected in an average amount of 1.5 nmol l-1. The mean leukotriene E4/creatinine ratio in urine increased from 0.02 in healthy subjects to 0.11 in patients with liver cirrhosis and to 1.2 mumol leukotriene E4 mol-1 creatinine in patients with hepatorenal syndrome. These results indicate that cysteinyl leukotrienes may play an important role in the mediator network responsible for the development of the hepatorenal syndrome in patients with severe liver disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499462     DOI: 10.1111/j.1365-2362.1989.tb00195.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 2.  Pathogenesis of ascites and hepatorenal syndrome.

Authors:  S P Wilkinson; K P Moore; V Arroyo
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Increased urinary leukotriene E(4) during febrile attacks in the hyperimmunoglobulinaemia D and periodic fever syndrome.

Authors:  J Frenkel; M A Willemsen; C M Weemaes; L Dorland; E Mayatepek
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

Review 4.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease.

Authors:  Stefano Fiorucci; Pasquale Rapacciuolo; Bianca Fiorillo; Rosalinda Roselli; Silvia Marchianò; Cristina Di Giorgio; Martina Bordoni; Rachele Bellini; Chiara Cassiano; Paolo Conflitti; Bruno Catalanotti; Vittorio Limongelli; Valentina Sepe; Michele Biagioli; Angela Zampella
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

Review 6.  New clues to the pathophysiology of hepatorenal failure.

Authors:  F Lang; W Gerok; D Häussinger
Journal:  Clin Investig       Date:  1993-02

7.  Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders.

Authors:  E Mayatepek; W D Lehmann; J Fauler; D Tsikas; J C Frölich; R B Schutgens; R J Wanders; D Keppler
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 8.  The hepatorenal syndrome.

Authors:  G Van Roey; K Moore
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

9.  Enhanced levels of leukotriene B(4) in synovial fluid in Lyme disease.

Authors:  E Mayatepek; D Hassler; M Maiwald
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

Review 10.  Liver cytoprotection by prostaglandins.

Authors:  J Quiroga; J Prieto
Journal:  Pharmacol Ther       Date:  1993       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.